A CAR T Therapy for KRAS-Driven Tumors

KRAS is a cell-growth gene that in mutant, fast-growth form drives some of the most intractable cancers. But a new type of CAR T cell immunotherapy developed by a group led by Daniel Powell Jr., PhD, of Pathology and Laboratory Medicine, can target KRAS-mutant cells. The researchers demonstrated the effectiveness of the new immunotherapy in rodent models of KRAS-driven lung, pancreatic and kidney cancers, and the strategy the team used to develop the new therapy should be broadly useful for making new types of CAR T cells.